Exact Mass: 574.3227152
Exact Mass Matches: 574.3227152
Found 500 metabolites which its exact mass value is equals to given mass value 574.3227152,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
CucurbitacinA
Cucurbitacin A is a cucurbitacin. Cucurbitacin A is a natural product found in Hintonia standleyana, Cucumis prophetarum, and other organisms with data available.
Herbimycin
A 19-membered macrocyle incorporating a benzoquinone ring and a lactam functionality. It is an ansamycin antibiotic that induces apoptosis and displays antitumour effects. C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D012294 - Rifamycins D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors
Ganoderic acid K
Ganoderic acid K is found in mushrooms. Ganoderic acid K is a constituent of Ganoderma lucidum (reishi) Constituent of Ganoderma lucidum (reishi). Ganoderic acid K is found in mushrooms.
Ganoderic acid alpha
Ganoderic acid alpha is found in mushrooms. Ganoderic acid alpha is a constituent of Ganoderma lucidum (reishi). Constituent of Ganoderma lucidum (reishi). Ganoderic acid alpha is found in mushrooms.
Cyclo(Arg-Gly-Asp-D-Phe-Val)
herbimycin a
3-{1-[6,7-Diethoxy-2-(morpholin-4-yl)quinazolin-4-yl]piperidin-4-yl}-1,6-dimethyl-1,2,3,4-tetrahydroquinazoline-2,4-dione
C31H38N6O5 (574.2903537999999)
PA(8:0/18:2(10E,12Z)+=O(9))
PA(8:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:2(10E,12Z)+=O(9)/8:0)
PA(18:2(10E,12Z)+=O(9)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/8:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/18:2(9Z,11E)+=O(13))
PA(8:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:2(9Z,11E)+=O(13)/8:0)
PA(18:2(9Z,11E)+=O(13)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/8:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/18:3(10,12,15)-OH(9))
PA(8:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:3(10,12,15)-OH(9)/8:0)
PA(18:3(10,12,15)-OH(9)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/8:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/18:3(9,11,15)-OH(13))
PA(8:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:3(9,11,15)-OH(13)/8:0)
PA(18:3(9,11,15)-OH(13)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/8:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Cucurbitacin A
Cucurbitacin a is a member of the class of compounds known as cucurbitacins. Cucurbitacins are polycyclic compounds containing the tetracyclic cucurbitane nucleus skeleton, 19-(10->9b)-abeo-10alanost-5-ene (also known as 9b-methyl-19-nor lanosta-5-ene), with a variety of oxygenation functionalities at different positions. Cucurbitacin a is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Cucurbitacin a can be found in cucumber, which makes cucurbitacin a a potential biomarker for the consumption of this food product.
Spirostan-2,3,27-triol, triacetate, (2.alpha.,3.beta.,5.alpha.,25S)-
1-benzoyl-2-methoxy-8,8-dimethyl-4,5-bis(3-methylbut-2-enyl)-7-[(3-methyl-4-acetoxy-but-2-enyl)]endo-bicyclo[3.3.1]non-2-ene-4,9-dione
3beta-O-(2-O-acetyl-alpha-L-thevetosyl)-14beta-hydroxy-7-en-5beta-card-20(22)-enolide|3??-O-(2-O-Acetyl-??-L-thevetosyl)-14??-hydroxy-7-en-5??-card-20(22)-enolide|7,8-dehydrocerberin
15alpha-hydroxy-16-dehydroxy-16(24)-en-foetidinol-3-O-beta-D-xylopyranoside
6-O-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]-beta-D-fructofuranosyl-(2->1)-alpha-D-glucopyranoside
12-O-decanoyl-7-oxo-5-ene-phorbol-13-acetate|12-O-neodecanoyl-7-oxo-5-enephorbol-13-acetate|daphwanin
3beta-O-(2-O-acetyl-alpha-L-acofriosyl)-16-anhydrogitoxigenin|vallarisoside
Glu Asp Arg Arg
Ganoderic acid alpha
Ganoderic Acid K
Ala Ile Trp Trp
C31H38N6O5 (574.2903537999999)
Ala Leu Trp Trp
C31H38N6O5 (574.2903537999999)
Ala Trp Ile Trp
C31H38N6O5 (574.2903537999999)
Ala Trp Leu Trp
C31H38N6O5 (574.2903537999999)
Ala Trp Trp Ile
C31H38N6O5 (574.2903537999999)
Ala Trp Trp Leu
C31H38N6O5 (574.2903537999999)
Asp Arg Val Trp
Asp Arg Trp Val
Asp Val Arg Trp
Asp Val Trp Arg
Asp Trp Arg Val
Asp Trp Val Arg
Glu Ile Lys Trp
Glu Ile Trp Lys
Glu Lys Ile Trp
Glu Lys Leu Trp
Glu Lys Trp Ile
Glu Lys Trp Leu
Glu Leu Lys Trp
Glu Leu Trp Lys
Glu Trp Ile Lys
Glu Trp Lys Ile
Glu Trp Lys Leu
Glu Trp Leu Lys
Phe Pro Arg Arg
Phe Arg Pro Arg
Phe Arg Arg Pro
His Lys Lys Tyr
His Lys Gln Tyr
His Lys Tyr Lys
His Lys Tyr Gln
His Gln Lys Tyr
His Gln Tyr Lys
His Tyr Lys Lys
His Tyr Lys Gln
His Tyr Gln Lys
Ile Ala Trp Trp
C31H38N6O5 (574.2903537999999)
Ile Glu Lys Trp
Ile Glu Trp Lys
Ile Lys Glu Trp
Ile Lys Trp Glu
Ile Met Arg Arg
Ile Arg Met Arg
Ile Arg Arg Met
Ile Arg Thr Trp
Ile Arg Trp Thr
Ile Thr Arg Trp
Ile Thr Trp Arg
Ile Trp Ala Trp
C31H38N6O5 (574.2903537999999)
Ile Trp Glu Lys
Ile Trp Lys Glu
Ile Trp Arg Thr
Ile Trp Thr Arg
Ile Trp Trp Ala
C31H38N6O5 (574.2903537999999)
Lys Glu Ile Trp
Lys Glu Leu Trp
Lys Glu Trp Ile
Lys Glu Trp Leu
Lys His Lys Tyr
Lys His Gln Tyr
Lys His Tyr Lys
Lys His Tyr Gln
Lys Ile Glu Trp
Lys Ile Trp Glu
Lys Lys His Tyr
Lys Lys Asn Trp
Lys Lys Trp Asn
Lys Lys Tyr His
Lys Leu Glu Trp
Lys Leu Trp Glu
Lys Asn Lys Trp
Lys Asn Gln Trp
Lys Asn Trp Lys
Lys Asn Trp Gln
Lys Gln His Tyr
Lys Gln Asn Trp
Lys Gln Trp Asn
Lys Gln Tyr His
Lys Trp Glu Ile
Lys Trp Glu Leu
Lys Trp Ile Glu
Lys Trp Lys Asn
Lys Trp Leu Glu
Lys Trp Asn Lys
Lys Trp Asn Gln
Lys Trp Gln Asn
Lys Tyr His Lys
Lys Tyr His Gln
Lys Tyr Lys His
Lys Tyr Gln His
Leu Ala Trp Trp
C31H38N6O5 (574.2903537999999)
Leu Glu Lys Trp
Leu Glu Trp Lys
Leu Lys Glu Trp
Leu Lys Trp Glu
Leu Met Arg Arg
Leu Arg Met Arg
Leu Arg Arg Met
Leu Arg Thr Trp
Leu Arg Trp Thr
Leu Thr Arg Trp
Leu Thr Trp Arg
Leu Trp Ala Trp
C31H38N6O5 (574.2903537999999)
Leu Trp Glu Lys
Leu Trp Lys Glu
Leu Trp Arg Thr
Leu Trp Thr Arg
Leu Trp Trp Ala
C31H38N6O5 (574.2903537999999)
Met Ile Arg Arg
Met Leu Arg Arg
Met Arg Ile Arg
Met Arg Leu Arg
Met Arg Arg Ile
Met Arg Arg Leu
Asn Lys Lys Trp
Asn Lys Gln Trp
Asn Lys Trp Lys
Asn Lys Trp Gln
Asn Gln Lys Trp
Asn Gln Trp Lys
Asn Trp Lys Lys
Asn Trp Lys Gln
Asn Trp Gln Lys
Pro Phe Arg Arg
Pro Arg Phe Arg
Pro Arg Arg Phe
Gln His Lys Tyr
Gln His Tyr Lys
Gln Lys His Tyr
Gln Lys Asn Trp
Gln Lys Trp Asn
Gln Lys Tyr His
Gln Asn Lys Trp
Gln Asn Trp Lys
Gln Trp Lys Asn
Gln Trp Asn Lys
Gln Tyr His Lys
Gln Tyr Lys His
Arg Asp Val Trp
Arg Asp Trp Val
Arg Phe Pro Arg
Arg Phe Arg Pro
Arg Ile Met Arg
Arg Ile Arg Met
Arg Ile Thr Trp
Arg Ile Trp Thr
Arg Leu Met Arg
Arg Leu Arg Met
Arg Leu Thr Trp
Arg Leu Trp Thr
Arg Met Ile Arg
Arg Met Leu Arg
Arg Met Arg Ile
Arg Met Arg Leu
Arg Pro Phe Arg
Arg Pro Arg Phe
Arg Arg Phe Pro
Arg Arg Ile Met
Arg Arg Leu Met
Arg Arg Met Ile
Arg Arg Met Leu
Arg Arg Pro Phe
Arg Thr Ile Trp
Arg Thr Leu Trp
Arg Thr Trp Ile
Arg Thr Trp Leu
Arg Val Asp Trp
Arg Val Trp Asp
Arg Trp Asp Val
Arg Trp Ile Thr
Arg Trp Leu Thr
Arg Trp Thr Ile
Arg Trp Thr Leu
Arg Trp Val Asp
Thr Ile Arg Trp
Thr Ile Trp Arg
Thr Leu Arg Trp
Thr Leu Trp Arg
Thr Arg Ile Trp
Thr Arg Leu Trp
Thr Arg Trp Ile
Thr Arg Trp Leu
Thr Trp Ile Arg
Thr Trp Leu Arg
Thr Trp Arg Ile
Thr Trp Arg Leu
Val Asp Arg Trp
Val Asp Trp Arg
Val Arg Asp Trp
Val Arg Trp Asp
Val Trp Asp Arg
Val Trp Arg Asp
Trp Ala Ile Trp
C31H38N6O5 (574.2903537999999)
Trp Ala Leu Trp
C31H38N6O5 (574.2903537999999)
Trp Ala Trp Ile
C31H38N6O5 (574.2903537999999)
Trp Ala Trp Leu
C31H38N6O5 (574.2903537999999)
Trp Asp Arg Val
Trp Asp Val Arg
Trp Glu Ile Lys
Trp Glu Lys Ile
Trp Glu Lys Leu
Trp Glu Leu Lys
Trp Ile Ala Trp
C31H38N6O5 (574.2903537999999)
Trp Ile Glu Lys
Trp Ile Lys Glu
Trp Ile Arg Thr
Trp Ile Thr Arg
Trp Ile Trp Ala
C31H38N6O5 (574.2903537999999)
Trp Lys Glu Ile
Trp Lys Glu Leu
Trp Lys Ile Glu
Trp Lys Lys Asn
Trp Lys Leu Glu
Trp Lys Asn Lys
Trp Lys Asn Gln
Trp Lys Gln Asn
Trp Leu Ala Trp
C31H38N6O5 (574.2903537999999)
Trp Leu Glu Lys
Trp Leu Lys Glu
Trp Leu Arg Thr
Trp Leu Thr Arg
Trp Leu Trp Ala
C31H38N6O5 (574.2903537999999)
Trp Asn Lys Lys
Trp Asn Lys Gln
Trp Asn Gln Lys
Trp Gln Lys Asn
Trp Gln Asn Lys
Trp Arg Asp Val
Trp Arg Ile Thr
Trp Arg Leu Thr
Trp Arg Thr Ile
Trp Arg Thr Leu
Trp Arg Val Asp
Trp Thr Ile Arg
Trp Thr Leu Arg
Trp Thr Arg Ile
Trp Thr Arg Leu
Trp Val Asp Arg
Trp Val Arg Asp
Trp Trp Ala Ile
C31H38N6O5 (574.2903537999999)
Trp Trp Ala Leu
C31H38N6O5 (574.2903537999999)
Trp Trp Ile Ala
C31H38N6O5 (574.2903537999999)
Trp Trp Leu Ala
C31H38N6O5 (574.2903537999999)
Tyr His Lys Lys
Tyr His Lys Gln
Tyr His Gln Lys
Tyr Lys His Lys
Tyr Lys His Gln
Tyr Lys Lys His
Tyr Lys Gln His
Tyr Gln His Lys
Tyr Gln Lys His
OKOHA-PA
C28H47O10P (574.2906691999999)
1,1-(decane-1,10-diyl)bis[4-amino-2-methylquinolinium] diacetate
C34H46N4O4 (574.3518875999999)
N-{4-[(1-Hydroxycarbamoyl-2-methyl-propyl)-(2-morpholin-4-YL-ethyl)-sulfamoyl]-4-pentyl-benzamide
C29H42N4O6S (574.2824912000001)
herbimycin a
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D012294 - Rifamycins D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors
[(E,6R)-6-[(2S,9R,10R,13R,14S,16R)-2,16-dihydroxy-9-(hydroxymethyl)-4,4,13,14-tetramethyl-3,11-dioxo-2,7,8,10,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate
[(2S,3R,4R,5S)-2-[(1S,2R,4R,5S,7S,11S,12S,15R,16S)-4,5-dihydroxy-2,16-dimethyl-8-oxo-9-oxatetracyclo[9.7.0.02,7.012,16]octadecan-15-yl]-5-ethyl-4-hydroxy-6-methylheptan-3-yl] hydrogen sulfate
[(1S)-1-carboxy-2-[2-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[(1R,2R)-2-hydroxy-1-[[(2S,4R)-4-propylpyrrolidine-2-carbonyl]amino]propyl]oxan-2-yl]sulfanyl-1H-imidazol-5-yl]ethyl]-trimethylazanium
[(4Z,6E,10E)-8,13,14,17-tetramethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D012294 - Rifamycins D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors
[(2R)-1-octanoyloxy-3-phosphonooxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2R)-2-octanoyloxy-3-phosphonooxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2R)-1-octanoyloxy-3-phosphonooxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[(2R)-2-octanoyloxy-3-phosphonooxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
7,8-Dehydrocerberin
A cardenolide glycoside that is the 7,8-dehydroderivative of cerberin. Isolated from Cerbera manghas, it exhibits cytotoxic activity.
2-[(2R,5S,8S,11S)-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-5-(phenylmethyl)-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
(6R)-6-[(3S,10S,13R,14R,15R,17R)-12-acetyloxy-3,15-dihydroxy-4,4,10,13,14-pentamethyl-7,11-dioxo-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid
N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-methyl-3-indolyl)acetamide
C34H46N4O4 (574.3518875999999)
[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
C28H47O10P (574.2906691999999)
[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
C28H47O10P (574.2906691999999)
[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
C28H47O10P (574.2906691999999)
[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
C28H47O10P (574.2906691999999)
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
C28H47O10P (574.2906691999999)
[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
C28H47O10P (574.2906691999999)
2-(3,4-Dimethoxyphenyl)ethyl 2,3,4-tri-O-methyl-alpha-(L)-rhamnopyranosyl(1.rar.3)-2,4,6-tri-O-methyl-beta-(D)-glucopyranoside
2-[[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-pentanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy-3-propanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
1-[3-(2-{5-hydroxy-1,6,6-trimethyl-4-oxo-3,7-dioxaspiro[bicyclo[3.2.1]octane-2,2'-oxan]-5'-yl}ethyl)-2,2-dimethyl-6-methylidenecyclohexyl]-2-(2-oxooxolan-3-ylidene)ethyl acetate
methyl (5ar,6r,7s,7as,7br,9as,13as,13bs,15as,15bs)-6-(acetyloxy)-7,13a-dihydroxy-5a-[(1r)-1-hydroxyethyl]-7b,9a,12,15a-tetramethyl-3-oxo-5h,6h,7h,7ah,8h,9h,10h,13h,14h,15h,15bh-chryseno[2,1-c]oxepine-13b-carboxylate
(1s)-1-[(1s,3r)-3-{2-[(1s,2s,5r,5's)-5-hydroxy-1,6,6-trimethyl-4-oxo-3,7-dioxaspiro[bicyclo[3.2.1]octane-2,2'-oxan]-5'-yl]ethyl}-2,2-dimethyl-6-methylidenecyclohexyl]-2-(2-oxooxolan-3-ylidene)ethyl acetate
5,7-dihydroxy-2-{1-hydroxy-5-[(3-hydroxy-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl)methyl]-6-methyl-2-oxo-1,5,8,8a-tetrahydronaphthalen-4a-yl}chromen-4-one
[(1s,9s,10r,11r,17s)-12-{[(4r,12r,13s,16s,17r,18s,20r,21e)-16-methyl-15-oxa-1,11-diazahexacyclo[15.3.1.0⁴,¹².0⁴,²⁰.0⁵,¹⁰.0¹³,¹⁸]henicosa-5,7,9-trien-21-ylidene]methyl}-8,14-diazapentacyclo[9.5.2.0¹,⁹.0²,⁷.0¹⁴,¹⁷]octadeca-2,4,6,12-tetraen-10-yl]methanol
(1r,2r,5s,6r,10r,11s,12s,15r,16r,18s,19r)-16-(acetyloxy)-6-(furan-3-yl)-11-hydroxy-1,5,10,15-tetramethyl-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-18-yl benzoate
methyl (5ar,6r,7s,7as,7br,9as,13as,13bs,15as,15br)-6-(acetyloxy)-7,13a-dihydroxy-5a-[(1s)-1-hydroxyethyl]-7b,9a,12,15a-tetramethyl-3-oxo-5h,6h,7h,7ah,8h,9h,10h,13h,14h,15h,15bh-chryseno[2,1-c]oxepine-13b-carboxylate
(6r)-6-[(3r,3ar,7s)-3,7-dihydroxy-3a,6,6,9a,11,11a-hexamethyl-4,10-dioxo-1h,2h,3h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-6-(acetyloxy)-2-methyl-4-oxohexanoic acid
6-[(3as,4r,7r,9ar,11r,11as)-11-(acetyloxy)-4,7-dihydroxy-3a,6,6,9a,11a-pentamethyl-3,10-dioxo-1h,2h,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-4-oxoheptanoic acid
methyl (5ar,6r,7s,7as,7br,9as,13as,13bs,15as,15bs)-7-(acetyloxy)-6,13a-dihydroxy-5a-(1-hydroxyethyl)-7b,9a,12,15a-tetramethyl-3-oxo-5h,6h,7h,7ah,8h,9h,10h,13h,14h,15h,15bh-chryseno[2,1-c]oxepine-13b-carboxylate
14-(4-hydroxy-5,6-dimethyl-3-oxoheptan-2-yl)-2,15-dimethyl-9-oxo-18-oxapentacyclo[8.8.0.0¹,¹⁷.0²,⁷.0¹¹,¹⁵]octadec-7-en-5-yl 2,3-dihydroxy-3-methylbutanoate
8-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-5,7-dihydroxy-3,6-bis(3-methylbut-2-en-1-yl)-2-(2,4,5-trihydroxyphenyl)chromen-4-one
(3r)-3-[(2r,3r,6s)-4-hydroxy-2,3-dimethyl-6-[(2r)-5-methyl-2-(2-methylprop-1-en-1-yl)hex-5-en-1-yl]-6-(3-methylbut-2-en-1-yl)-5,7-dioxo-2,3-dihydro-1-benzopyran-8-yl]-3-phenylpropanoic acid
2-[2,5-bis(acetyloxy)-4,7-dihydroxy-3a,3b,6,9a-tetramethyl-dodecahydro-2h-cyclopenta[a]phenanthren-1-ylidene]-6-methylhept-5-enoic acid
methyl (5ar,6r,7s,7as,7br,9as,13as,13bs,15as,15bs)-7-(acetyloxy)-6,13a-dihydroxy-5a-[(1r)-1-hydroxyethyl]-7b,9a,12,15a-tetramethyl-3-oxo-5h,6h,7h,7ah,8h,9h,10h,13h,14h,15h,15bh-chryseno[2,1-c]oxepine-13b-carboxylate
methyl (5ar,6r,7s,7as,7br,9ar,13as,13bs,15as,15bs)-7-(acetyloxy)-6,13a-dihydroxy-5a-[(1r)-1-hydroxyethyl]-7b,9a,15a-trimethyl-12-methylidene-3-oxo-5h,6h,7h,7ah,8h,9h,10h,11h,13h,14h,15h,15bh-chryseno[2,1-c]oxepine-13b-carboxylate
2'-o-acetyl cerleaside a
{"Ingredient_id": "HBIN006174","Ingredient_name": "2'-o-acetyl cerleaside a","Alias": "NA","Ingredient_formula": "C32H46O9","Ingredient_Smile": "CC1C(C(C(C(O1)OC2CCC3(C(C2)CCC45C3CCC(C4=O)(C(CC5)C6=CC(=O)OC6)C)C)OC(=O)C)OC)O","Ingredient_weight": "574.7 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "349","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101338813","DrugBank_id": "NA"}
3β-o-(2'-o-acetyl-α-l-thevetosyl)-14β-hy-droxy-7-en-5β-card-20(22)-enolide
{"Ingredient_id": "HBIN008278","Ingredient_name": "3\u03b2-o-(2'-o-acetyl-\u03b1-l-thevetosyl)-14\u03b2-hy-droxy-7-en-5\u03b2-card-20(22)-enolide","Alias": "NA","Ingredient_formula": "C32H46O9","Ingredient_Smile": "CC1C(C(C(C(O1)OC2CCC3(C4CCC5(C(CCC5(C4=CCC3C2)O)C6=CC(=O)OC6)C)C)OC(=O)C)OC)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "526","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}